Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its pediatric cough granules have successfully completed a Phase II clinical trial for treating acute bronchitis in adults, indicating potential for market expansion and increased revenue [1][2][6]. Group 1: Clinical Trial Information - The pediatric cough granules received clinical approval for adult acute bronchitis on March 11, 2022, with a total R&D expenditure of approximately 21.65 million RMB [1]. - The Phase II clinical trial involved 330 participants, randomized into high-dose (30g/day), low-dose (15g/day), and placebo groups, with results showing significant efficacy in reducing cough severity and improving related symptoms [6][7]. - The trial demonstrated that both high and low doses were more effective than the placebo, with no serious adverse events reported [6][7]. Group 2: Market Position and Financial Performance - The pediatric cough granules are the company's proprietary product and have generated nearly 90 million RMB in sales in 2024, marking a 73% increase [3][11]. - The market for cough and bronchitis medications includes competitors such as Kyoto Nishikyo's syrup and Taiji Group's products, with significant sales figures reported for these alternatives [4][3]. - The overall sales of cough and phlegm-relieving traditional Chinese medicine exceeded 15.8 billion RMB in the first half of 2024 across various healthcare settings [4]. Group 3: Future Outlook and Strategic Plans - The company plans to leverage the successful clinical trial results to enhance its product portfolio and expand market reach, focusing on innovative drug development [11][15]. - The strategic focus includes optimizing resource allocation and increasing the proportion of innovative drug revenue, which currently stands at 11% [11]. - Future growth is anticipated through the development of a diverse product matrix and improved operational efficiency, aiming for sustainable growth over the next 3-5 years [15].
湖南方盛制药股份有限公司 关于小儿荆杏止咳颗粒成人急性气管-支气管炎（风寒化热证）获得II期临床试验总结报告的公告